News & Events

WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced it has entered into a new clinical research collaboration with Bristol-Myers Squibb Company (NYSE:BMY) to evaluate the safety and efficacy of WindMIL Therapeutics’ marrow-infiltrating lymphocytes (MILs™) in combination with Bristol-Myers Squibb’s nivolumab (Opdivo®), a PD-1 immune checkpoint inhibitor, in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to, or have relapsed on, an anti-PD-1-containing regimen.